INSIGHTS ON CLINICAL TRIAL PARTNERING

• Working With A Specialty Oncology CRO Versus A Large Generalist CRO

  Specialty oncology CROs bridge the gap between traditional CRO operating models and the specialized needs of oncology sponsors by embedding deep oncology expertise across every function.

• Turning Urgency Into Progress And Advancing New Hope In AML

  A disrupted AML trial stabilized mid-study, cutting genetic testing turnaround to 1–2 days and keeping enrollment on track for patients who can't wait.

• Elevating Patient Centricity In Clinical Trials

  How can the integration of patient perspectives throughout the clinical trial process enhance engagement and outcomes?

• Executing Pediatric Gene Therapy Trials At The Site Level

  Pediatric gene therapy trials demand exceptional coordination at the site level, and these frontline insights can help you manage protocol complexity and balance operations with family‑centered care.

• Do You Know Today, What Your Trial Will Spend Tomorrow?

  7/13/2026

  Fragmented data and outdated forecasting can derail trial budgets. Real-time financial and operational insights improve accuracy and spending control.

• Building Blocks For Strategic Patient Support In Clinical Trials

  12/8/2025

  Let’s talk about some tangible building blocks necessary to achieve the next evolution of patient support and explore the effects of strategic payment, budgeting, and logistics solutions.

• Targeted Protein Degraders: Transforming Oral Therapeutics

  8/11/2025

  CDMOs play a critical role in TPD development by offering specialized infrastructure and analytical capabilities to support the transition from preclinical research to clinical supply and commercialization.

• Maximizing Site Performance: The Hidden Benefits Of Unified eConsent And EDC

  12/6/2024

  Disconnected systems for eConsent and EDC create inefficiencies that burden clinical trial teams, but modern integrated platform solutions are streamlining operations.

• Redefining Site Feasibility

  3/12/2026

  Site feasibility is becoming a major source of startup delays as early requests, pre‑award outreach, and unclear communication create inaccurate projections and wasted effort.